• Introduction of the concept of cardiovascular age
• Recommending more frequent monitoring of patients with FRS ≥5%
• Using apolipoprotein B or non-HDL-C as alternate lipid markers
• Addition of chronic kidney disease as a high-risk feature
• Reduced age for treatment in diabetes
• Specific recommendations about health behaviours
• New recommendation about statin adverse effects
• Use of GRADE recommendations and process

apoB, apolipoprotein B; FRS, Framingham Risk Score; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HDL-C, high-density lipoprotein cholesterol.